A Study of 99mTc-3PRGD2 Injection in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

January 18, 2019

Study Completion Date

January 18, 2019

Conditions

Healthy

Interventions

DRUG

99mTc niacinamide polyethylene glycol bicyclic RGD peptide (99mTc-3PRGD2)

Single dose

Trial Locations (1)

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

collaborator

Beijing Pharbers Genesis Pharmaceutical Technology Co., Ltd.

INDUSTRY

collaborator

MedAlly Solutions Co., Ltd.

UNKNOWN

lead

RDO Pharm.

INDUSTRY

NCT03974685 - A Study of 99mTc-3PRGD2 Injection in Healthy Volunteers | Biotech Hunter | Biotech Hunter